Friday, 16 October 2026European Markets

VERALLIA And ELOPAK Have A High Dividend Yield And Return On Equity In The Packaging & Containers Industry.

Loading stream...

(vianews) - verallia (vrla.pa) is among this list of stock assets with the highest dividend rate and return on equity on the packaging & containers industry.

financial asset price forward dividend yield return on equity
verallia (vrla.pa) €36.00 4.57% 44.03%
elopak (elo.ol) kr32.30 3.83% 22.46%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. verallia (vrla.pa)

4.57% forward dividend yield and 44.03% return on equity

verallia société anonyme manufactures and sells glass packaging products for beverages and food products worldwide. it provides bottles for still and sparkling wines, spirits, beers, soft drinks, and oils. the company offers jars for baby food, dairy products, jams, honey, spreads, condiments, sauces, and preserves. verallia société anonyme was founded in 1827 and is based in courbevoie, france.

earnings per share

as for profitability, verallia has a trailing twelve months eps of €4.01.

pe ratio

verallia has a trailing twelve months price to earnings ratio of 8.98. meaning, the purchaser of the share is investing €8.98 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 44.03%.

revenue growth

year-on-year quarterly revenue growth grew by 30.7%, now sitting on 3.86b for the twelve trailing months.

sales growth

verallia's sales growth is 27.9% for the current quarter and 19.7% for the next.

volatility

verallia's last week, last month's, and last quarter's current intraday variation average was 0.51%, 0.32%, and 1.24%.

verallia's highest amplitude of average volatility was 0.76% (last week), 1.07% (last month), and 1.24% (last quarter).

yearly top and bottom value

verallia's stock is valued at €36.00 at 06:40 est, way below its 52-week high of €44.86 and way higher than its 52-week low of €26.58.

more news about verallia.

2. elopak (elo.ol)

3.83% forward dividend yield and 22.46% return on equity

elopak asa manufactures and supplies paper-based packaging solutions for liquid food in norway and internationally. it offers pure-pak cartons for chilled and aseptic applications; common roll fed aseptic carton; and packaging products. it also provides packaging solutions for detergent, fabric softener, and hand wash products. in addition, the company offers standard flexo, super flexo, uv-flexo, and offset litho printing services, as well as digital print proofs and machine print proofs on paper board. further, it provides machine and equipment through spare part webshop. elopak asa was founded in 1957 and is based in oslo, norway.

earnings per share

as for profitability, elopak has a trailing twelve months eps of kr2.76.

pe ratio

elopak has a trailing twelve months price to earnings ratio of 11.7. meaning, the purchaser of the share is investing kr11.7 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.46%.

yearly top and bottom value

elopak's stock is valued at kr32.30 at 06:40 est, way above its 52-week high of kr26.00.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 12, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 3.83%.

moving average

elopak's value is way above its 50-day moving average of kr22.63 and way above its 200-day moving average of kr23.47.

more news about elopak.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com